ITM Showcases Innovative Dosimetry Data at EANM 2025 Event
ITM Isotope Technologies' Upcoming Presentation at EANM 2025
ITM Isotope Technologies Munich SE, a prominent figure in the radiopharmaceutical biotech sector, is set to reveal significant dosimetry data from its COMPETE trial at the upcoming European Association of Nuclear Medicine (EANM) congress. This exciting event will occur in early October, where ITM will not only present its findings but also host a symposium related to targeted theranostics for the treatment of neuroendocrine tumors (NETs).
Focus of the Oral Presentation
Dr. Emmanuel Deshayes from Montpellier will be the key speaker for the oral presentation entitled "Dosimetry of [177Lu]Lu-edotreotide in patients with gastro-enteropancreatic neuroendocrine tumors: Results from the COMPETE Phase 3 trial". The presentation is scheduled for October 6, 2025, from 3:00 pm to 3:10 pm CEST at Room 117. It aims to share pivotal insights drawn from the dosimetry data, which has shown promising results in treating grade 1 and grade 2 tumors.
Details on the Satellite Symposium
In addition to the oral presentation, ITM will host a symposium titled "SSTR-Targeting Theranostics in NETs and Beyond: Milestones and New Frontiers" on October 5, 2025, from 1:30 pm to 2:30 pm CEST in Room 114. Dr. Ken Herrmann, the Chair of the Nuclear Medicine Department at the University Hospital Essen, will lead this session. Attendees can expect discussions regarding the scientific advancements and clinical applications of investigational agents, particularly focusing on 177Lu-edotreotide.
Noteworthy Speakers at the Symposium
The symposium will feature several esteemed speakers who will delve into various aspects of NET treatment:
- Prof. Vikas Prasad from St. Louis will discuss the origins of 177Lu-edotreotide in NETs.
- Dr. Rocío García-Carbonero from Spain will share insights on how to translate clinical evidence into practice in NET treatments.
- Prof. Damian Wild will explore future opportunities in SSTR-targeted therapies, emphasizing the evolution of treatment methodologies.
The Significance of the COMPETE Trial
The COMPETE trial has been an essential study comparing 177Lu-edotreotide against everolimus in patients facing inoperable, progressive gastroenteropancreatic NETs. This trial aimed to deliver a deeper understanding of progression-free survival rates and how 177Lu-edotreotide could serve as a superior treatment option.
ITM: Leading the Way in Radiopharmaceutical Development
ITM Isotope Technologies Munich SE is committed to evolving the landscape of radiopharmaceuticals. With their advanced therapeutic agents and focus on diagnostics, they are well-positioned to address the pressing needs of patients suffering from difficult-to-treat cancers. The company's mission revolves around enhancing patient outcomes through innovative solutions and sustained research efforts.
Meet the Expert Sessions
In conjunction with the symposium, ITM will offer unique opportunities for attendees to interact with experts in the field. Dr. Julia Fricke from the University Hospital Basel will host two “Meet the Expert” sessions focusing on ITM-63 and ITM-64, a theranostic pair pivotal for diagnosing and treating SSTR-positive tumors.
Contact Information for ITM
For media inquiries, contacts are available at:
Corporate Communications
Kathleen Noonan/Julia Westermeir
Phone: +49 89 329 8986 1500
Email: communications@itm-radiopharma.com
Investor Relations
Ben Orzelek
Phone: +49 89 329 8986 1009
Email: investors@itm-radiopharma.com
Frequently Asked Questions
What is the COMPETE trial about?
The COMPETE trial assesses the effectiveness of 177Lu-edotreotide versus everolimus in patients with neuroendocrine tumors.
Where will ITM's symposium be held?
ITM's symposium will take place at EANM 2025 in Room 114.
When is the presentation by Dr. Emmanuel Deshayes?
The presentation is scheduled for October 6, 2025, from 3:00 pm to 3:10 pm CEST.
Who are the featured speakers in the symposium?
The symposium will feature experts like Prof. Vikas Prasad and Dr. Rocío García-Carbonero.
How does ITM aim to improve patient outcomes?
ITM focuses on developing innovative radiopharmaceuticals that provide effective treatment options for cancer patients.
About The Author
Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.